Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
News|Articles|November 18, 2020
Almac Group Receives Award from COVID-19 Therapeutics Accelerator to Produce Remdesivir
Author(s)Pharmaceutical Technology Editors
Almac Sciences has been granted an award by the COVID-19 Therapeutics Accelerator for the development of an efficient and scalable production process for remdesivir.
Advertisement
Almac Sciences, a member of Almac Group, has been granted an award worth US $500,000 by the COVID-19 Therapeutics Accelerator for the development of an efficient and scalable production process for remdesivir.
According to a Nov. 17, 2020 press release, the funding will enable Almac Sciences to apply its plan to improve the overall route of synthesis to remdesivir, including application of synthetic flow methodology and biocatalysis. This plan will ultimately lower raw material usage, increase global yields, and lower the overall cost of goods for the remdesivir development process.
“We are delighted to receive funding from the Therapeutics Accelerator to apply our skills in the fight against COVID-19,” said Dr. Stefan Mix, head of Biocatalysis, Almac Sciences, in the press release. “With the skillset of our multidisciplinary teams, we are confident that our developmental approach to the manufacture of remdesivir will positively impact patients’ lives who are in urgent need, regardless of their location.”
“This project highlights Almac’s strength in technology deployment through application of both innovative flow chemistry and biocatalysis technologies to support development of processes which are economical, greener, and safer to perform,” added Prof. Tom Moody, vice-president of Technology Development and commercialization at Almac Sciences and Arran Chemical Company, in the press release.
Source:
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement